Abstract

Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. The identification of non-peptide B1 antagonists has been a notable advance in the kinin field that will allow evaluation of their therapeutic potential in the clinical realm. The current review is a high level summary of our contributions to the area that culminated in the discovery of a clinical candidate.

Keywords: Analgesics, pain, inflammation, bradykinin, covalent binding, P-glycoprotein